Abstract C212: A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats.

Author(s):  
Dan Zhou ◽  
Yuan Liu ◽  
Josephine Ye ◽  
Weiwen Ying ◽  
Shijie Zhang ◽  
...  
2013 ◽  
Vol 221 ◽  
pp. S236
Author(s):  
Hiroko Hitotsumachi ◽  
Yasuo Kodama ◽  
Shuichi Ohkubo ◽  
Kazuhiko Besshi ◽  
Kazuhiko Yonekura ◽  
...  

Author(s):  
А. Г. Гунин ◽  
Н. Н. Голубцова ◽  
Н. К. Корнилова

Целью работы стало исследование содержания белка теплового шока 90 ( HSP 90) в фибробластах дермы человека от эмбрионального развития и до глубокой старости (от 20 нед беременности до 85 лет), а также определение значения HSP 90 для возрастных изменений численности фибробластов в дерме человека. HSP 90, ядерный антиген пролиферирующих клеток ( PCNA ) выявляли в срезах кожи непрямым иммуногистохимическим методом. Результаты показали, что в коже человека от 20 нед беременности до 20 лет доля фибробластов дермы с положительной окраской на HSP 90 остается постоянной. С 21 года до 60 лет наблюдают планомерное уменьшение доли фибробластов дермы, имеющих положительную окраску на HSP 90. У людей 61-85 лет происходит резкое увеличение доли фибробластов дермы с положительной окраской на HSP 90. Возрастные изменения содержания HSP 90 положительных фибробластов в дерме статистически не связаны с возрастным уменьшением общего количества и доли PCNA -положительных фибробластов в дерме. The aim of this work was to examine the content of heat shock protein 90 ( HSP 90) in fibroblasts of human dermis from the development until deep aging (from 20 weeks of pregnancy until 85 years old), and defining of a role of HSP 90 in age-dependent changes in the number of fibroblasts in the dermis. HSP 90, proliferating cells nuclear antigen ( PCNA ) were detected with indirect immunohistochemical technique. Results showed that a portion of fibroblasts with positive staining for HSP 90 in the dermis is not changed from 20 weeks of development to 20 years old. Percent of HSP 90 positive fibroblasts in dermis is decreased from 21 to 60 years old. From 61 year, the number of HSP 90 positive fibroblasts in dermis is increased. Age-related changes in the number of HSP 90 positive fibroblasts is not statistically associated with an age-related decrease in a total number and percent of PCNA positive fibroblasts the dermis.


2011 ◽  
Vol 287 (4) ◽  
pp. 2410-2422 ◽  
Author(s):  
Georgina N. Montagna ◽  
Carlos A. Buscaglia ◽  
Sylvia Münter ◽  
Christian Goosmann ◽  
Friedrich Frischknecht ◽  
...  

2018 ◽  
Vol 15 (3) ◽  
pp. 934-946 ◽  
Author(s):  
Martina Benešová ◽  
Christoph A. Umbricht ◽  
Roger Schibli ◽  
Cristina Müller

Author(s):  
Hiroyuki Abe ◽  
Amane Sasada ◽  
Shigeki Tabata ◽  
Minako Abe

Despite advances in chemotherapeutic regimens, ovarian cancer has a poor prognosis. Therefore important effective treatments are urgently needed. Many studies have reported that the immune system plays a critical role in disease progression and overall survival. One known effective immunotherapy is the dendritic cell (DC)-based vaccine pulsed with tumor-associated antigens. This chapter reports on a method of production of a novel DC-based vaccine. The key technologies are (a) monocyte collection without leukapheresis, (b) monocyte expansion, (c) production of dendritic cells, (d) multiple overlapping long peptides with heat shock protein 70, and (e) combination immunotherapy approach. The next generation of immunotherapy for ovarian cancer will be focused on combination approaches that simultaneously augment immunity while preventing local immune suppression. Possible combinations which might be useful to help patients with ovarian cancer are summarized in this chapter.


Sign in / Sign up

Export Citation Format

Share Document